Faggioni A, Corradini C, Venanzoni M, Cardi G, Bevere F, Barile G, Zompetta C, Frati L
Dipartimento di Medicina Sperimentale, Università degli Studi di Roma La Sapienza.
J Exp Pathol. 1987 Summer;3(4):471-7.
In the present study we report the results of the EBV-specific antibody response in 30 Italian NPC patients, 20 other head and neck tumor patients and 20 healthy controls. Histopathologically, the tumors were classified as squamous cell carcinoma (WHO 1), nonkeratinizing carcinoma (WHO 2) and undifferentiated carcinoma (WHO 3). Immunofluorescence tests were performed in order to evaluate the antibodies against VCA, EA and the EBV nuclear antigen (EBNA), and the antibody dependent cellular cytotoxicity test was used to detect the EBV specific antibodies against membrane antigens. IgG and IgA antibodies to EBV VCA and IgG antibodies to EA were significantly and consistently higher in the NPC patients than in other patients or controls. Moreover, only the WHO 2 and WHO 3 histological types of NPC resulted associated with EBV. ADCC titers ranging from 1:480 to 1:15360 have been determined; low ADCC titers were prevalent among the VCA-IgA positive donors, while VCA-IgA negative donors presented high ADCC titers. Our results look consistent with other previous results in low-risk and high-risk areas. In conclusion, EBV serology seems to be extremely useful for diagnostic purposes; however, in order to assess a prognostic value of the above markers, a greater number of patients followed for a longer period is needed.
在本研究中,我们报告了30例意大利鼻咽癌患者、20例其他头颈肿瘤患者及20名健康对照者的EBV特异性抗体反应结果。在组织病理学上,肿瘤被分类为鳞状细胞癌(WHO 1型)、非角化癌(WHO 2型)和未分化癌(WHO 3型)。进行免疫荧光试验以评估针对VCA、EA和EBV核抗原(EBNA)的抗体,并使用抗体依赖性细胞毒性试验检测针对膜抗原的EBV特异性抗体。鼻咽癌患者中针对EBV VCA的IgG和IgA抗体以及针对EA的IgG抗体显著且持续高于其他患者或对照者。此外,仅WHO 2型和WHO 3型组织学类型的鼻咽癌与EBV相关。已测定的ADCC效价范围为1:480至1:15360;低ADCC效价在VCA-IgA阳性供体中普遍存在,而VCA-IgA阴性供体呈现高ADCC效价。我们的结果与之前在低风险和高风险地区的其他结果一致。总之,EBV血清学似乎对诊断极为有用;然而,为了评估上述标志物的预后价值,需要对更多患者进行更长时间的随访。